
    
      Postmenopausal women with HR-positive, HER2-negative metastatic breast cancer achieving
      clinical benefit after the induction chemotherapy for visceral disease with sign(s) and/or
      symptom(s) will be recruited to receive study the maintenance treatment of everolimus plus
      exemestane.
    
  